CANCER DRUG PRICE CONTROLS FACE A LIMIT: 159 MEDICINE PACKS MAY ESCAPE REDUCTIONS UNDER NEW NPPA RULES

October 30, 2026

NEW DELHI, OCTOBER 30, 2026: India's latest cancer medicine price-control measures may not translate into lower prices for every affected product, with 159 medicine packs potentially seeing no price reduction under the new rules of the National Pharmaceutical Pricing Authority (NPPA).

The development raises questions about how the revised pricing framework will affect patients and families facing the high costs of cancer treatment. Although price regulation is intended to improve affordability, its practical impact may vary across individual medicines and product packs.

For patients requiring prolonged treatment, even modest differences in medicine prices can influence household medical expenditure. Consequently, the extent to which the revised rules reduce the cost of cancer medicines will depend on how the new provisions apply to specific products.

The NPPA's revised data indicate that the maximum retail prices of 484 out of 643 listed medicine packs are expected to fall, while the remaining 159 will retain their existing prices. The unchanged prices do not necessarily indicate a regulatory failure, as some products may already comply with the prescribed trade-margin limit.

However, patient-rights advocates have called for closer scrutiny of the figures, particularly because some of the medicines retaining their prices are exceptionally expensive. These include selumetinib, listed at ₹10.22 lakh for a pack of 60 capsules, and alectinib, priced at approximately ₹4.31 lakh for a pack of 224 units.

The 30 per cent trade-margin cap on 137 cancer drugs is scheduled to take effect on November 9. The central question remains whether the new framework will substantially improve access to expensive cancer treatments, particularly for patients who must pay for medicines out of their own pockets. Pharmaceutical manufacturers' pricing data and the calculation of trade margins are likely to remain central to the debate over the effectiveness of the policy.